id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9450 R33185 |
Rihtman (Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2013 | Vacuum and/or forceps assisted childbirth | at least 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No Controls: epilepsy indication |
0.25 [0.03;2.26] C excluded (control group) |
1/29 5/40 | 6 | 29 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9451 R33220 |
Rihtman (Valproate) (Controls unexposed, NOS) (Mixed indications), 2013 | Vacuum and/or forceps assisted childbirth | at least 1st trimester excluded | prospective cohort | unexposed (general population or NOS) | Adjustment: No |
0.42 [0.04;3.94] C excluded (exposition period) |
1/29 4/51 | 5 | 29 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9432 R33126 |
Borthen (Valproate) (Controls exposed to Lamotrigine, sick), 2010 | Delivery Cephalic vaginal with forceps or vacuum | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.73 [0.41;1.32] C excluded (control group) |
21/215 30/233 | 51 | 215 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9434 R33134 |
Borthen (Valproate) (Controls unexposed, disease free), 2010 | Delivery Cephalic vaginal with forceps or vacuum | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
1.40 [0.90;2.20] excluded (control group) |
21/215 28,546/362,302 | 28,567 | 215 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9436 R33142 |
Borthen (Valproate) (Controls unexposed, sick), 2010 | Delivery Cephalic vaginal with forceps or vacuum | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: No | 1.19 [0.74;1.93] C | 21/215 155/1,863 | 176 | 215 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9300 R32377 |
Endo (Valproate) (Controls unexposed, disease free), 2004 | Forceps deliveries | at least 1st trimester | retrospective cohort | unexposed, disease free excluded | Adjustment: No |
2.84 [0.31;25.91] C excluded (control group) |
1/5 53/656 | 54 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9301 R32392 |
Endo (Valproate) (Controls unexposed, sick), 2004 | Forceps deliveries | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 0.43 [0.01;33.60] C | 1/5 0/1 | 1 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 1.18 [0.73;1.90] | 177 | 220 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate) (Controls unexposed, sick; 2: Valproate) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 9300, 9432, 9434, 9450